DDI Between BI Empagliflozin (10773) and Verapamil

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Verapamil; Drug: BI 10773

Study type: Interventional

Funder types: Industry

Identifiers

NCT01276301

1245.43

2010-023059-27 (EudraCT Number)

Details and patient eligibility

About

Relative bioavailability of BI 10773 given alone and together with verapamil

Enrollment: 16 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

healthy male and female subjects

Exclusion criteria

Any relevant deviation from healthy conditions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

16 participants in 2 patient groups

Reference

Experimental group

Description:

single dose BI 10773

Treatment:

Drug: BI 10773

Drug: BI 10773

Test

Active Comparator group

Description:

single dose BI 10773 + single dose verapamil

Treatment:

Drug: BI 10773

Drug: BI 10773

Drug: Verapamil